Brugada syndrome, Short QT syndrome and Catecholaminergic Polymorphic Ventricular 48
Tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. 49
Introduction 57
Ever since the first case was reported at the end of 2019, the SARS-COV-2 virus and 58 associated lung disease COVID-19 has spread throughout the world and has become a 59 pandemic. In particular, the high transmission rate of the virus has made it a threat to public 60 health globally. 1, 2 Currently, there is no proven effective therapy against the virus, and the 61 impact on other diseases is also uncertain. 62 SARS-CoV-2 is an RNA virus, a member of coronavirus family of viruses, similar to 63 SARS-CoV. 3 Like SARS-CoV, SARS-CoV-2 infects humans by binding to the 64 angiotensin-converting enzyme 2 (ACE2) receptor on the surface of the cell through its spike 65 domain. 3 Infected patients present with a variety of manifestations. The most common clinical 66 symptom is fever (88.7%). Other symptoms include cough (67.8%), shortness of breath 67 (18.7%), myalgia or arthralgia (14.9%), headache (13.6%), diarrhea (3.8%), sore throat 68 (13.9%), and sputum production (33.7%) and fatigue (38.1%). 4 Studies have shown that 69 while the vast majority of patients have minor symptoms, it is also possible for infected cases 70 to become critically ill, especially older individuals (above 60 years old) or patients with 71 comorbidities. 1, 2 Severely affected patients may have acute respiratory distress (15.6%) which 72 requires invasive mechanical ventilation (14.5%) and extracorporeal membrane oxygenation 73 (2.9%). 4 5 A registry of 1099 cases with COVID-19 reported a higher prevalence of hypertension 76 (23.7% vs. 13.4%) and coronary artery disease (5.8% vs. 1.8%) in severely affected versus 77 non-severely affected patients. 4 Another study, of 138 hospitalized COVID-19 78 patients compared patients admitted to the intensive care unit (ICU) and non-ICU patients. 79
Higher rates of hypertension (58.3% vs. 21.6%, p <0.001) and cardiovascular disease (25.0% 80 vs. 10.8%, p=0.04) were observed in ICU patients. 1 This indicates that patients with 81 pre-existing cardiovascular disease may have a worse prognosis than others although age could 82 be one of the confounders. Furthermore, it is also essential to understand that although most 83 clinical presentations relate to the respiratory system, the disease may also impact on the 84 cardiovascular system. 5 Besides the respiratory system, ACE2 is expressed in the human 85 cardiovascular system including the heart 6 and a number of mechanisms have been put 86 forward whereby SARS-CoV-2 may cause myocardial injury. These include mechanisms 87 involving derangement of ACE2 signal pathways (animal studies have shown that cellular 88 ACE2 levels decrease upon SARS-CoV infection), 6 cytokine storm and myocarditis. 7,8 89
Occurrence of myocardial involvement and severity thereof varies among affected 90 individuals. While myocardial damage evidenced by high cardiac markers such as hs-TnI has 91 been recognized 9 and fulminant myocarditis has been reported, 8 whether cardiovascular 92 complications include malignant arrhythmias is not yet known. In the afore-mentioned study 93 of 138 hospitalized COVID-19 patients, arrhythmia (not further specified) was reported in 17% 6 of total patients and in 16 of 36 patients admitted to the ICU. 1 Therefore, an arrhythmogenic 95 effect of COVID-19 could be expected, potentially contributing to disease outcome. This may 96 be of importance for patients with an increased risk for cardiac arrhythmias, either secondary to 97 acquired conditions, co-morbidities, or consequent to inherited syndromes. Management of 98 patients with inherited arrhythmia syndromes such as Long QT syndrome, Brugada syndrome, 99 Short QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia in the 100 setting of the COVID-19 pandemic may prove particularly challenging. Depending on the 101 inherited defect involved, these patients may be susceptible to pro-arrhythmic effects of 102 COVID-19-related issues such as fever, stress, electrolyte disturbances and use of antiviral 103 drugs. Hence, additional precautions and preventive measures are recommended, including 104 ECG monitoring, aggressive antipyretic treatment, and more stringent social distancing to 105 prevent infection. 10 We here describe the potential COVID-19 associated risks and therapeutic 106 considerations for patients with distinct inherited arrhythmia syndromes and provide 107 recommendations for their monitoring and management during this pandemic. 108
Long QT syndrome 109
The Long QT syndrome (LQTS) is characterised by abnormally prolonged ventricular 110 repolarization and an increased risk of the malignant arrhythmia Torsades de Pointes and 111 ventricular fibrillation that may lead to sudden death. LQTS is an inheritable condition caused 112 by pathogenic variants in genes encoding ion channels (primarily KCNQ1, KCNH2, SCN5A). 7 An often-faced clinical situation, however, is acquired QT-interval prolongation, that occurs 114 for instance during myocardial ischemia, hypothermia, as a result of treatment with a wide 115 range of drugs, hypokalaemia or sepsis. Severe QTc-prolongation due to these conditions 116 might similarly result in malignant arrhythmias. Rather commonly, patients who have severe 117 forms of acquired QT-prolongation also have a genetic predisposition for 118 QTc-prolongation, 11,12 but without such extreme provocation these patients generally have 119 normal QT-intervals. In fact, many LQTS patients may also have QT-intervals within normal 120 limits in resting conditions, 13 although this still puts them at higher risk for malignant 121 arrhythmias, 14 especially during provocations such as the use of QTc-prolonging drugs. 15 122 Whereas severe forms of inherited LQTS often surface during (early) childhood (from infants 123 to adolescents), 14,16 acquired QT-prolongation generally occurs in older patients because these 124 critical provocative events more often occur in older patients. 125
Long QT syndrome and COVID-19 126
There are several issues that require attention when discussing COVID-19 in relation to 127 inheritable or acquired QT-prolongation. 128
The most important determinant of risk for malignant arrhythmias in patients with LQTS 129 or in acquired QT-prolongation, is the use of one or more QTc prolonging drugs in the setting 130 of severe manifestations of COVID-19. Many drugs (either with cardiac or non-cardiac 131 indications) have the ability to block cardiac potassium currents, impairing ventricular 132 8 repolarisation with subsequent prolongation of the QT-interval and an increased risk for 133 malignant arrhythmias. 15 In addition, many drugs may alter drug metabolism, e.g. due to 134 inhibition of CYP3A4, which may further increase plasma levels of QT-prolonging drugs and 135 further increase risk. Of special interest in COVID-19 is that there are indications that 136 chloroquine and hydroxychloroquine might be of value. 17 137
Chloroquine is one of the most widely used anti-malarial drugs world-wide, but it has also 138 been investigated as a potential broad-spectrum anti-viral drug. 18 Amongst its mechanisms, 139 chloroquine appears to interfere with the terminal glycosylation of ACE2 and may thus 140 negatively influence virus-receptor binding and abrogate infection. 19-21 However, chloroquine 141 is closely related to quinidine, and while the latter is used as an anti-arrhythmic drug in 142 Brugada syndrome and idiopathic forms of ventricular fibrillation, it is also well known for its 143 QT-prolonging effects and has been associated with QT related malignant arrhythmias. 144
Luckily, the QT-prolonging effect of chloroquine is very modest, and in general it does not 145 result in clinically significant QT-prolongation in patients without LQTS. 22 146 Hydroxychloroquine sulfate, a less toxic derivative of chloroquine, is widely used in the 147 chronic treatment of autoimmune diseases without significant effects on ECG parameters, 23 148 and was recently shown to also efficiently inhibit SARS-CoV-2 infection in vitro. 24 However, 149 both chloroquine and hydroxychloroquine are metabolised by CYP3A4, and COVID-19 150 treatment with (hydroxy)chloroquine can be combined with additional anti-viral treatments 9 such as ritonavir plus lopinavir (both potent CYP3A4 inhibiting drugs; their combination is 152 associated with QT-prolongation), azithromycin (besides a macrolide antibiotic also 153 investigated for its antiviral properties, with also (weak) CYP3A4 inhibition and associated 154 with QT-prolongation) 25,26 , or remdesivir (an investigational drug for which metabolism and 155 possible QT prolonging effects are not yet resolved). Combining (hydroxy)chloroquine with 156 these drugs might thus result in higher plasma levels and significant QT-prolongation. Hence, 157
we advise monitoring QT-intervals and cardiac rhythm if starting these drugs given the 158 increased risk for malignant arrhythmias (Figure 1 ). In addition, physicians should be aware of 159 the alpha-blocking effects of (hydroxy)chloroquine, which might result in hypotension. 160
Another issue is fever. The effect of fever is, in contrast to patients with for example BrS 161 (see below), much less evident in patients with LQTS. A possible exception are patients, with 162 specific LQTS 2 mutations, presenting with fever-triggered arrhythmias which are based on 163 temperature sensitive mutant channels (i.e. less current with higher temperature). 27 As most 164 patients hospitalised for COVID-19 have fever, 4 patients with known LQTS will thus generally 165 not be at increased risk. The separate contribution of fever in acquired QT-prolongation is not 166 well known, but sepsis is a denominator of risk of acquired QT-prolongation 28 , and septic 167 shock is one of the clinical scenarios in COVID-19. 4 168 Finally, interpretation of the QT-interval is not easy, 29 but guidance is available. 13 While 169 COVID-19 patients admitted to Intensive Care Units will often have continuous ECG 170 monitoring available, ECG monitoring of inpatients who are being treated in an airborne 171 isolation room can be challenging. Nevertheless, if possible, we advise ( Figure 1) to 172 monitor QT-intervals at baseline and at 4h after administration of (hydroxy)chloroquine and/or 173 anti-viral therapy in patients with congenital or acquired LQTS, patients already taking other 174 QT-prolonging drugs, and patients with structural heart disease or bradycardia. A second ECG 175 is recommended after 1-3 days. In all other patients, QTc-interval monitoring should be 176 performed 24h after start of therapy. During the course of (hydroxy)chloroquine and/or 177 anti-viral therapy, QTc-interval monitoring is furthermore indicated in case of worsening 178 kidney/liver function and electrolyte disorders (in particular K + , Ca 2+ and Mg 2+ ), especially in 179 LQTS patients or patients with abnormal QT-intervals at baseline. Of particular concern is the 180 COVID-19 associated diarrhea which may lead to hypokalemia with adverse effects on the 181 The importance of fever in BrS patients is now well-established. [33] [34] [35] In 24 patients with 211
BrS, 3 of whom had a fever-triggered cardiac arrest, the increase in body temperature reduced 212 the PR interval in control individuals, but increased PR interval, QRS width, and the maximum 213 J-point in BrS patients. 34 Another study showed that fever-associated BrS seems to be 214 associated with a higher future risk of LTE's compared to drug-induced type 1 pattern. 35 
215
Finally, fever seems to be particularly relevant in children. 33 Indeed, in a registry with 216 symptomatic BrS patients (the SABRUS registry) approximately 6% of LTE's were associated 217 with fever and the highest rate of fever-triggered LTE's was observed in the very young (65%, 218 age ≤5 years). In the age range 16 to 70 years, only 4% of the LTE's was related to fever. In the 219 elderly (>70 years) this percentage increased to 25%. 33 220
In the setting of fever, the presence of a pathogenic variant in SCN5A may be particularly 221 relevant. In a single center series of 111 patients with BrS, 22 presented with a cardiac arrest, 4 222 of which were fever related. Three of these 4 patients harbored a pathogenic variant in 223 SCN5A. 34 In the SABRUS registry, the percentage of SCN5A pathogenic variants was 77% in 224 children and 27% in adults with a LTE. 33 The authors also performed an analysis of all 225 published cases (up to 2018) with fever-triggered LTE's (40 patients in 22 reports) revealed the 226 presence of a putatively pathogenic variant in SCN5A was found in 13 (68%) of 19 patients 227 tested. 33 Moreover, in a multicenter pediatric population of 106 patients, 10 patients had a LTE 228 during follow-up, which was triggered by fever in 27%; all of the latter patients were positive 229 for a pathogenic SCN5A variant. Finally, preliminary data in a pediatric cohort indicated that 230 mainly children with a SCN5A mutation developed a type 1 ECG during fever (43.8% of 231 children who developed a type 1 ECG during fever had a SCN5A mutation vs 4.2% of children 232 without a type 1 during fever) and had events during follow-up (7/21 vs 0/47). 36 These studies 233 collectively indicate that sodium channel function is sensitive to temperature. This sensitivity 234 may be due to altered temperature-sensitive kinetics, in particular accelerated inactivation, 37 235 and/or decreased sodium channel expression at higher temperatures. 38 preferably paracetamol/acetaminophen, or eventually ibuprofen). More generally, BrS patients, 265
in particular those with a pathogenic or likely pathogenic variant in SCN5A, are advised to 266 self-isolate in their private environment. 267
Short QT syndrome 268
Short QT syndrome (SQTS) is a familial arrhythmia syndrome characterized by short QT 269 intervals on the ECG and a significant rate of ventricular arrhythmias. 41 It is a heterogeneous 270 disease caused by pathogenic variants in at least three different potassium channel genes 271 (KCNH2, KCNQ1 and KCNJ2) and the cardiac chloride-bicarbonate exchanger gene 272 (SLC4A3). 42 It is an extremely rare disease; in a recent systematic literature review only 110 273 cases were described. 43 No specific triggers for LTE, including fever, have been described. 274
Hence, based on current knowledge, SQTS patients do not seem to be at particular risk when 275 they are affected by Potential drugs for COVID-19 patients, like chloroquine, might actually be beneficial for 277 SQTS patients due to lengthening of their QT-interval, as has been suggested by modelling 278 data for SQTS type 1 (KCNH2-related 44 ) and type 3 (KCNJ2 related 44, 45 ). There are no clinical 279 data as far as we are aware. 280
We therefore do not believe that there is a particular concern when SQTS patients are 281 infected with SARS-CoV-2. LTE. An increased heart rate alone (pacing-induced), as an important symptom of fever, does 292 not appear to be sufficient for the induction of ventricular arrhythmias. 48 Fever, as a specific 293 trigger has not been described. Whether or not the stressful circumstances that COVID-19 294 patients find themselves in will lead to an increased burden of arrhythmias can only be 295 speculated upon. 296
The antiviral therapy proposed for COVID-19 is not expected to lead to increased risk. 297
The only potential deleterious pharmacological interaction in these patients are drugs with 298 alpha or beta adrenoceptor mimetic activity, which may be used in cases in need of 299 hemodynamic support. Intravenous epinephrine has been used to unmask ventricular 300 arrhythmias and initial data suggested that epinephrine was more effective than exercise testing 301 in unmasking ventricular arrhythmias. 49 Later studies revealed, however, a low sensitivity and 302 high specificity (with the exercise test as the gold standard 50 ). Nevertheless, based on their 303 pathophysiological mechanism of action, epinephrine, isoproterenol and dobutamine, all alpha 304 and/or B1 receptor agonists, should probably be avoided. Milrinone, the most widely used 305 phosphodiesterase 3 inhibitor, acts by decreasing the degradation of cyclic adenosine 306 monophosphate (cAMP). This may potentially stimulate the RyR2 receptor and must thus be 307 used with caution. However, with continuation of the beta blockers (as we recommend, see 308 below) this may not be that relevant because betablockers suppress milrinone-induced 309 increased Ca-leak. 51 CPVT patients, in particular those who were symptomatic prior to 310 diagnosis, should stay on their beta blocker treatment with or without flecainide as long as is 311 tolerated hemodynamically. Flecainide does have interactions with Ritonavir/Lopinavir and 312
chloroquine, yet we believe that it is an important enough therapy not to stop in these 313 particularly stressful circumstances. 314
Based on the above we also suggest avoidance of epinephrine in the setting of a VT/VF 315 arrest if possible. This is probably the only resuscitation setting where epinephrine is 316 contraindicated. 52 317
Conclusion 318
Patients with inherited arrhythmia syndromes may be at an increased pro-arrhythmic risk 319 
